Cumberland Pharmaceuticals (CPIX) Tops Q2 EPS by 5c, Revenues Beat

Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q2 EPS of $0.08, $0.05 better than the analyst estimate of $0.03. Revenue for the quarter came in at $9.6 million versus the consensus estimate of $9.27 million.

"As the world continues to adapt to a new way of life during the pandemic, we are working hard to manage our business, secure our supply chain and ensure the ongoing delivery of our products to support patient care during these unprecedented times," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Our facilities have remained open, and we have continued to operate our business, while working to maintain compliance with the many laws and regulations we fall under as a publicly traded, pharmaceutical company. We continue to make progress toward our goal of building a specialty pharmaceutical business that delivers sustained growth, profitable operations, and long-term value."

For earnings history and earnings-related data on Cumberland Pharmaceuticals (CPIX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Ennis (EBF) Reports In-Line Q1 EPS
• Reliance Global Group names new CTO, COO, and EVP for AI push